These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10524892)

  • 1. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial.
    de Reijke TM; Keuppens FI; Whelan P; Kliment J; Robinson MR; Rea LA; Sylvester RJ
    J Urol; 1999 Nov; 162(5):1658-64; discussion 1664-5. PubMed ID: 10524892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893.
    Fosså SD; Curran D; Aaronson NK; Keuppens F; Kliment J; Robinson MR; DeReijke TM; Hetherington J; Kil PJ; Rea LA
    Eur Urol; 2000 May; 37(5):541-51. PubMed ID: 10765092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.
    Boel K; Van Poppel H; Goethuys H; Derluyn J; Vandenbroucke F; Popelier G; Casselman J; Billiet I; Vanuytsel L; Paridaens R; Baert L
    Anticancer Res; 1999; 19(3B):2157-61. PubMed ID: 10472324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial.
    Van Poppel H; van den Broucke F; Derluyn J; Popelier G; Casselman J; Billiet I; van Uytsel L; Paridaens R; Baert L
    J Urol; 1993 Jun; 149(6):1485-7. PubMed ID: 8501794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
    Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer.
    Vandenbroucke F; Van Poppel H; Derluyn J; Popelier G; Casselman J; Billiet I; Vanuytsel L; Paridaens R; Baert L
    Am J Clin Oncol; 1995 Jun; 18(3):263-6. PubMed ID: 7747716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).
    Newling DW; Fossa SD; Tunn UW; Kurth KH; de Pauw M; Sylvester R
    J Urol; 1993 Dec; 150(6):1840-4. PubMed ID: 8230517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
    Krege S; Giani G; Meyer R; Otto T; Rübben H
    J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.
    Osborne CK; Blumenstein B; Crawford ED; Coltman CA; Smith AY; Lambuth BW; Chapman RA
    J Clin Oncol; 1990 Oct; 8(10):1675-82. PubMed ID: 2213104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Keuppens F; Whelan P; Carneiro de Moura JL; Newling D; Bono A; Denis L; Robinson M; Mahler C; Sylvester R; De Pauw M
    Cancer; 1993 Dec; 72(12 Suppl):3863-9. PubMed ID: 8252505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
    Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM
    J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases.
    Fontana D; Bertetto O; Fasolis G; Berruti A; Tarabuzzi R; Pagani G; Buniva T; Zolfanelli R; Pallotti S; Frezzotti L; Bumma C; Rossetti SR; Dogliotti L
    Tumori; 1998; 84(1):39-44. PubMed ID: 9619712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
    Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
    Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
    Rosendahl I; Kiebert GM; Curran D; Cole BF; Weeks JC; Denis LJ; Hall RR
    Prostate; 1999 Feb; 38(2):100-9. PubMed ID: 9973095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.
    Granfors T; Modig H; Damber JE; Tomic R
    J Urol; 2006 Aug; 176(2):544-7. PubMed ID: 16813885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
    Jørgensen T; Müller C; Kaalhus O; Danielsen HE; Tveter KJ
    Eur Urol; 1995; 28(1):40-6. PubMed ID: 8521893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.